Microneedle drug delivery market seen doubling by 2030

The Business Research Company says the global microneedle drug delivery systems market is on track to rise from $5.86 billion in 2025 to $13.16 billion by 2030 as demand builds for less invasive drug and vaccine delivery. North America held the largest regional share in 2025, while obesity rates and self-care devices are adding momentum.

Why it matters: - Microneedle systems could make drug and vaccine delivery less painful and easier to use than traditional injections. - The market’s projected growth points to stronger demand for minimally invasive treatments, self-administered care, and wearable delivery technologies. - Rising obesity rates add a practical use case for easier medication delivery, including obesity-related therapies.

What happened: - The Business Research Company published its "Microneedle Drug Delivery Systems Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The market is forecast to grow from $5.86 billion in 2025 to $6.92 billion in 2026. - The report projects the market will reach $13.16 billion by 2030. - North America was the largest regional market in 2025, with Europe ranked second.

The details: - The 2025-to-2026 increase implies an 18.1% CAGR. - The 2026-to-2030 outlook implies a 17.4% CAGR. - Historical growth was linked to more transdermal drug delivery research, greater patient preference for minimally invasive treatment, vaccination initiatives, more clinical trials using microneedle technologies, and improvements in microfabrication. - Future growth is expected to come from wider adoption of self-care medical devices, higher investment in biologics delivery technologies, wearable drug delivery systems, better treatment adherence, and more commercial microneedle products. - The report highlights dissolving microneedle technologies, painless drug delivery, vaccine applications, self-administered systems, and biodegradable microneedle materials as notable trends. - Microneedle drug delivery systems use arrays of tiny needles to deliver drugs, vaccines, or other therapeutic agents through the skin. - The needles penetrate the stratum corneum without reaching deeper nerve endings, which reduces pain compared with traditional injections. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report includes a free sample and a full report available online: Download the sample report and View the full market report.

Between the lines: - The growth forecast suggests microneedle technology is moving from niche research toward broader commercialization. - The focus on painless, self-administered delivery suggests the market is being shaped as much by patient convenience as by clinical performance. - The obesity reference shows the report is tying market demand to chronic disease management, not just vaccines.

What's next: - Microneedle adoption is expected to deepen as self-care devices, biologics delivery, and wearable systems expand. - Product development is likely to keep shifting toward dissolving and biodegradable formats. - The report points to continued commercialization through 2030 as the main driver of market expansion.

The bottom line: - Microneedle drug delivery is emerging as a fast-growing alternative to injections, with the strongest momentum coming from pain reduction, self-care use, and vaccine applications.